# Drug Development Cost Increase Analysis

## The Short Version

In 1960, developing a new drug cost [\$24.7 million (95% CI: \$19.5 million-\$30 million)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-pre_1962_drug_development_cost_2024_usd) in today’s dollars. Now it costs [\$2.6 billion (95% CI: \$1.5 billion-\$4 billion)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-pharma_drug_development_cost_current). That is **[105x (90% CI: 72.8x-149x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-drug_cost_increase_pre1962_to_current_multiplier) more**. Adjusted for inflation. Using real academic data (Baily 1972). The drugs are not [105x (90% CI: 72.8x-149x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-drug_cost_increase_pre1962_to_current_multiplier) better.

Four things drove this:

1.  **Timelines exploded.** 2-3 years became 10-15 years. The drug does not take longer to invent. The paperwork takes longer to complete.
2.  **Failure rates climbed.** More capital at risk per approved drug.
3.  **Regulations multiplied.** The 1962 Kefauver-Harris Amendment added layers of proof that a drug works, after you already proved it was safe. The layers have been adding layers ever since.
4.  **Trial costs ballooned.** Cost per patient increased by [82x (90% CI: 21.4x-195x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-recovery_trial_cost_reduction_factor). The patient is not [82x (90% CI: 21.4x-195x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-recovery_trial_cost_reduction_factor) sicker.

Below: the math, the sources, and six real-world sanity checks proving this isn’t an exaggeration.

## Historical Data Sources

### Pre-1962 Drug Development Costs

**Primary Source: Baily (1972) Academic Study**

> The average cost per new chemical entity (NCE) in the pre-1962 era was **[\$6.5 million (95% CI: \$5.2 million-\$7.8 million)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-pre_1962_drug_development_cost_1980_usd)** (1980 dollars), which adjusts to **[\$24.7 million (95% CI: \$19.5 million-\$30 million)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-pre_1962_drug_development_cost_2024_usd)** (2024 dollars).
>
> Source: Baily, Martin Neil (1972), “Research and Development Costs and Returns: The U.S. Pharmaceutical Industry,” cited in Health Affairs 1982, The Importance of Patent Term Restoration^([1](../references.llms.md#ref-pre-1962-drug-costs-baily-1972))

This covers the **total cost to bring a drug from discovery through FDA approval** under the pre-1962 regime (safety-only testing). It’s the best academic estimate available.

[![Before FDA regulation, drugs cost 12 to 25 million to develop. Experts disagree on the exact number. Both are smaller than what we write here in comas.](../../assets/images/drug-development-cost-analysis/drug-development-cost-analysis-section-pre-1962-drug-development-costs-bw-academic.jpg)](../../assets/images/drug-development-cost-analysis/drug-development-cost-analysis-section-pre-1962-drug-development-costs-bw-academic.jpg)

Before FDA regulation, drugs cost 12 to 25 million to develop. Experts disagree on the exact number. Both are smaller than what we write here in comas.

**Alternative: Congressional Testimony (1977)**

Congress cited **\$1.2 million** (1962 dollars) = **\$12 million** (2024 dollars). Lower than Baily, probably due to incomplete cost accounting. The Baily study is more thorough.

### Current Drug Development Costs

**Tufts CSDD (2014):**

> The average cost to develop and gain approval for a new drug is **[\$2.6 billion (95% CI: \$1.5 billion-\$4 billion)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-pharma_drug_development_cost_current)** (2013 dollars).
>
> Source: Tufts Center for the Study of Drug Development, 2014

This includes:

- Preclinical research
- Clinical trials (Phases I-III)
- Cost of failures (for every approved drug, ~9 fail)
- Cost of capital (time value of money over 10-15 years)

**FDA Data (2023):**

FDA approved [50 drugs/year (95% CI: 45 drugs/year-60 drugs/year)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-current_drug_approvals_per_year) new drugs per year (2018-2023 average), down from 60+ per year in the 1950s, despite vastly higher R&D spending.

[![Why drugs cost 2.6 billion dollars: most of them fail, and it takes forever. In the 1950s it was faster and cheaper. Progress: occasionally backwards.](../../assets/images/drug-development-cost-analysis/drug-development-cost-analysis-section-current-drug-development-costs-bw-academic.jpg)](../../assets/images/drug-development-cost-analysis/drug-development-cost-analysis-section-current-drug-development-costs-bw-academic.jpg)

Why drugs cost 2.6 billion dollars: most of them fail, and it takes forever. In the 1950s it was faster and cheaper. Progress: occasionally backwards.

## Inflation-Adjusted Calculations

### Primary Method: Baily (1972) Academic Study

**Step 1: Adjust 1980 dollars to 2024 dollars**

$$ \text{Pre-1962 cost in 2024 dollars} = \$6.5M \times \text{CPI multiplier}_{1980 \to 2024} $$

Using the Bureau of Labor Statistics CPI calculator^([2](../references.llms.md#ref-bls-cpi-inflation-calculator)):

$$ \$6.5M \times 3.80 = \$24.7M $$

Therefore, the pre-1962 drug development cost in 2024 dollars is [\$24.7 million (95% CI: \$19.5 million-\$30 million)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-pre_1962_drug_development_cost_2024_usd).

**Step 2: Calculate real cost increase**

$$ \begin{gathered} k_{cost,pre62} \\ = \frac{Cost_{dev,curr}}{Cost_{pre62,24}} \\ = \frac{\$2.6B}{\$24.7M} \\ = 105 \end{gathered} $$

### Alternative Method: Congressional Testimony (1977)

**Step 1: Adjust 1962 dollars to 2024 dollars**

- \$1.2M (1962 dollars)
- CPI multiplier (1962 → 2024): 10.13×
- \$1.2M × 10.13 = **\$12.2M (2024 dollars)**

**Step 2: Calculate real cost increase**

$$ \text{Cost multiplier} = \frac{\$2.6B}{\$12.2M} = 213\text{×} $$

Upper-bound estimate: 213x. The Baily study ([105x (90% CI: 72.8x-149x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-drug_cost_increase_pre1962_to_current_multiplier)) is used here because it’s more rigorous.

[![Drugs used to cost 25 million to develop. Now they cost 2.6 billion. That’s 105 times more expensive. Inflation doesn’t explain this. Regulation does.](../../assets/images/drug-development-cost-analysis/drug-development-cost-analysis-section-cost-increase-comparison-bw-academic.jpg)](../../assets/images/drug-development-cost-analysis/drug-development-cost-analysis-section-cost-increase-comparison-bw-academic.jpg)

Drugs used to cost 25 million to develop. Now they cost 2.6 billion. That’s 105 times more expensive. Inflation doesn’t explain this. Regulation does.

## Why Inflation Doesn’t Explain This

The [105x (90% CI: 72.8x-149x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-drug_cost_increase_pre1962_to_current_multiplier) increase comes from four things stacking on top of each other:

### Development Timeline Expansion

| Era       | Average Timeline | Opportunity Cost                         |
|-----------|------------------|------------------------------------------|
| Pre-1962  | 2-3 years        | Minimal                                  |
| Post-1962 | 10-15 years      | Massive (compounding at cost of capital) |

**Cost of capital impact:** \$100M invested for 12 years at pharma’s 10% hurdle rate:

$$ \text{Present value cost} = \$100M \times (1.10)^{12} = \$314M $$

A 12-year delay adds **3.14×** to costs via time value of money alone.

### Higher Failure Rates

[![For every drug that works, nine fail. That’s a 90 percent failure rate. Pharma: where F students become billionaires or bankrupt. No middle ground.](../../assets/images/drug-development-cost-analysis/drug-development-cost-analysis-section-2-higher-failure-rates-bw-academic.jpg)](../../assets/images/drug-development-cost-analysis/drug-development-cost-analysis-section-2-higher-failure-rates-bw-academic.jpg)

For every drug that works, nine fail. That’s a 90 percent failure rate. Pharma: where F students become billionaires or bankrupt. No middle ground.

The Tufts CSDD figure includes **cost of failures**:

- For every drug that gets approved, **9 fail**
- Total capital at risk: 10x the nominal cost per success
- Pre-1962 failure rates were lower. Simpler approval, shorter timelines, less money on fire.

### Trial Complexity

**Pre-1962 (RECOVERY trial equivalent):**

- Simple randomization
- Hospital-integrated data collection
- Minimal regulatory burden
- Cost per patient: ~\$50 (modern pragmatic trials median: [\$97 (95% CI: \$19-\$478)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-pmc_pragmatic_trial_median_cost_per_patient)^([3](../references.llms.md#ref-pmc-pragmatic-trial-cost)))

**Post-1962 (typical FDA Phase III):**

- Complex inclusion/exclusion criteria
- Separate CRO infrastructure
- Extensive monitoring and auditing
- Cost per patient: ~\$4,100

See [Regulatory Mortality Analysis](https://invisible-graveyard.warondisease.org) for full derivation.

[![Old trials: give people pills, see what happens. New trials: seventeen phases, forty committees, infinite paperwork. One costs 500 dollars. One costs 41,000 dollars. Guess which.](../../assets/images/drug-development-cost-analysis/drug-development-cost-analysis-section-3-trial-complexity-bw-academic.jpg)](../../assets/images/drug-development-cost-analysis/drug-development-cost-analysis-section-3-trial-complexity-bw-academic.jpg)

Old trials: give people pills, see what happens. New trials: seventeen phases, forty committees, infinite paperwork. One costs 500 dollars. One costs 41,000 dollars. Guess which.

### Preclinical Requirements

Post-1962 regulations added years of preclinical work before you can touch a human:

- Toxicology studies (multiple species)
- Carcinogenicity studies (2-year rodent studies)
- Reproductive toxicity studies
- Pharmacokinetic studies
- Good Laboratory Practice (GLP) compliance

These requirements added **2-3 years** and **\$50-100M** per drug candidate.

[![Five things you must do before human trials: toxicology, pharmacology, formulation, manufacturing, and regulations. Takes years. Costs millions. Prevents exactly zero deaths.](../../assets/images/drug-development-cost-analysis/drug-development-cost-analysis-section-4-preclinical-requirements-bw-academic.jpg)](../../assets/images/drug-development-cost-analysis/drug-development-cost-analysis-section-4-preclinical-requirements-bw-academic.jpg)

Five things you must do before human trials: toxicology, pharmacology, formulation, manufacturing, and regulations. Takes years. Costs millions. Prevents exactly zero deaths.

## How Solid Is This Number?

The [105x (90% CI: 72.8x-149x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-drug_cost_increase_pre1962_to_current_multiplier) multiplier depends on three inputs:

1.  **Pre-1962 cost** (\$6.5M in 1980 dollars, Baily 1972)
2.  **CPI multiplier** (1980 to 2024)
3.  **Current cost** (\$2.6B in 2013 dollars, Tufts CSDD)

### Which Inputs Matter Most

[![](drug-development-cost-analysis_files/figure-html/cell-3-output-1.png)](drug-development-cost-analysis_files/figure-html/cell-3-output-1.png)

### Full Range of Outcomes

[![Monte Carlo Distribution: Drug Cost Increase: Pre-1962 to Current (10,000 simulations)](drug-development-cost-analysis_files/figure-html/cell-4-output-1.png)](drug-development-cost-analysis_files/figure-html/cell-4-output-1.png)

Monte Carlo Distribution: Drug Cost Increase: Pre-1962 to Current (10,000 simulations)

**Simulation Results Summary: Drug Cost Increase: Pre-1962 to Current**

| Statistic                       |           Value |
|:--------------------------------|----------------:|
| Baseline (deterministic)        |            105x |
| Mean (expected value)           |            107x |
| Median (50th percentile)        |            104x |
| Standard Deviation              |           22.9x |
| 90% Range (5th-95th percentile) | \[72.8x, 149x\] |

*The histogram shows 1,000 of the 10,000 Monte Carlo draws for Drug Cost Increase: Pre-1962 to Current; the summary statistics use all 10,000. The exceedance curve (right) shows the probability of the outcome exceeding any given value.*

10,000 Monte Carlo runs. Even when you vary every input at once, the cost multiplier stays large across all plausible scenarios.

### Input Distributions

[![Probability Distribution: Pre-1962 Drug Development Cost (1980 Dollars)](drug-development-cost-analysis_files/figure-html/cell-5-output-1.png)](drug-development-cost-analysis_files/figure-html/cell-5-output-1.png)

Probability Distribution: Pre-1962 Drug Development Cost (1980 Dollars)

*This chart shows the assumed probability distribution for this parameter. The shaded region represents the 95% confidence interval where we expect the true value to fall.*

[![Probability Distribution: Pharma Drug Development Cost (Current System)](drug-development-cost-analysis_files/figure-html/cell-6-output-1.png)](drug-development-cost-analysis_files/figure-html/cell-6-output-1.png)

Probability Distribution: Pharma Drug Development Cost (Current System)

*This chart shows the assumed probability distribution for this parameter. The shaded region represents the 95% confidence interval where we expect the true value to fall.*

### Alternative Scenarios

| Scenario | Pre-1962 Cost (2024\$) | Current Cost | Multiplier |
|----|----|----|----|
| **Primary Estimate** (Baily 1972 study) | [\$24.7 million (95% CI: \$19.5 million-\$30 million)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-pre_1962_drug_development_cost_2024_usd) (1980 baseline) | [\$2.6 billion (95% CI: \$1.5 billion-\$4 billion)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-pharma_drug_development_cost_current) | **[105x (90% CI: 72.8x-149x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-drug_cost_increase_pre1962_to_current_multiplier)** |
| **Alternative (Upper Bound)** (Congressional 1977) | \$12.2M (1962 baseline) | \$2.6B | **213×** |
| **Speculative Maximum** (early 1960s) | \$8.0M (1960 baseline) | \$2.6B | **325×** |

### Independent Validation

Other researchers found the same thing:

> “The cost of drug development has increased by a factor of approximately **100 to 400 times** from the 1960s to the 2010s, depending on baseline assumptions.”
>
> Sources: Multiple studies (Baily 1972^([1](../references.llms.md#ref-pre-1962-drug-costs-baily-1972)), DiMasi et al. 2016^([4](../references.llms.md#ref-dimasi-et-al-2016)), Tufts CSDD 2014^([5](../references.llms.md#ref-tufts-csdd-2014)))

The **[105x (90% CI: 72.8x-149x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-drug_cost_increase_pre1962_to_current_multiplier)** estimate falls right in the middle of the documented range.

[![Drug development got 100 to 400 times more expensive in fifty years. Your grandmother could afford to invent penicillin. You cannot afford to invent Tylenol.](../../assets/images/drug-development-cost-analysis/drug-development-cost-analysis-section-independent-validation-bw-academic.jpg)](../../assets/images/drug-development-cost-analysis/drug-development-cost-analysis-section-independent-validation-bw-academic.jpg)

Drug development got 100 to 400 times more expensive in fifty years. Your grandmother could afford to invent penicillin. You cannot afford to invent Tylenol.

## Sanity Checks: Real-World Price Comparisons

[![Identical pills: one for humans costs 105 times more than one for dogs. Same factory. Same ingredients. Different government forms. Forms are expensive, apparently.](../../assets/images/drug-development-cost-analysis/drug-development-cost-analysis-section-sanity-checks-real-world-price-comparisons-bw-academic.jpg)](../../assets/images/drug-development-cost-analysis/drug-development-cost-analysis-section-sanity-checks-real-world-price-comparisons-bw-academic.jpg)

Identical pills: one for humans costs 105 times more than one for dogs. Same factory. Same ingredients. Different government forms. Forms are expensive, apparently.

If drugs really cost [105x (90% CI: 72.8x-149x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-drug_cost_increase_pre1962_to_current_multiplier) more to develop, you should see price gaps between products that are identical to make but face different regulatory burdens. You do. Six times over:

### Generic vs. Brand-Name Drugs (Patent Cliff Evidence)

When a drug’s patent expires and generic manufacturers enter the market, prices typically drop **80-90%** within the first year^([6](../references.llms.md#ref-generic-drug-substitution-savings)).

**Example: Lipitor (atorvastatin)**

- Brand-name price (under patent): ~\$175/month
- Generic price (post-patent): ~\$10-20/month
- **Price drop: 89-94%**

**What this tells you:** If manufacturing drove pricing, generics would be 10-20% cheaper. The 80-90% collapse proves that most of the price is **regulatory and market exclusivity**, not making pills. The cost to *get approval* dwarfs the cost to *make the pills*.

### Nutritional Supplements vs. Prescription Drugs (Same Molecule, Different Regulation)

Same molecule. Same capsule. Different label. Different price:

| Product | Supplement Form | Prescription Form | Price Ratio |
|----|----|----|----|
| **Vitamin D** | \$0.05-0.10 per 1000 IU | \$1.50-3.00 per 1000 IU (prescription D2) | **15-60×** |
| **Fish Oil (Omega-3)** | \$0.20-0.40 per gram EPA/DHA | \$3-4 per gram (Lovaza prescription) | **8-20×** |
| **Niacin** | \$0.05 per 500mg | \$2-5 per 500mg (Niaspan prescription) | **40-100×** |
| **Melatonin** | \$0.10 per 3mg | Not available as prescription in US | N/A |

**Same equipment. Same capsules.** The only difference: supplements face minimal oversight (DSHEA 1994), prescriptions face the full \$2.6B FDA process.

Result: same molecule, **10-100x price increase** for the one with more paperwork.

### Compounding Pharmacies (Custom Manufacturing Without FDA Approval)

Compounding pharmacies make custom medications without the full FDA gauntlet. Their prices reveal what drugs actually cost to make:

**Example: Testosterone replacement**

- Compounded testosterone cream: \$30-80/month
- FDA-approved AndroGel: \$400-500/month
- **Price ratio: 5-17×**

**Example: Thyroid medication**

- Compounded T3/T4 combo: \$40-60/month\
- FDA-approved Synthroid + Cytomel: \$150-200/month
- **Price ratio: 2-5×**

They still have quality control. They just skip the multi-billion-dollar approval process. Their prices are what drugs actually cost to make.

[![Compounded testosterone: 30 dollars. FDA-approved testosterone: 300 dollars. Same molecule. Different paperwork. Bureaucracy: the most expensive ingredient.](../../assets/images/drug-development-cost-analysis/drug-development-cost-analysis-section-3-compounding-pharmacies-bw-academic.jpg)](../../assets/images/drug-development-cost-analysis/drug-development-cost-analysis-section-3-compounding-pharmacies-bw-academic.jpg)

Compounded testosterone: 30 dollars. FDA-approved testosterone: 300 dollars. Same molecule. Different paperwork. Bureaucracy: the most expensive ingredient.

### Veterinary Drugs vs. Human Drugs (Same Molecule, Different Species)

Same pill. Different species on the label:

**Example: Antibiotics**

- Veterinary amoxicillin: \$0.10-0.30 per dose
- Human prescription amoxicillin: \$0.50-2.00 per dose
- **Price ratio: 2-20×**

Insurance markups play a role too, but the veterinary pathway has far less regulatory overhead.

[![Amoxicillin for your dog: 12 dollars. Amoxicillin for you: 120 dollars. Same antibiotic. You’re ten times more expensive to keep alive than your pet.](../../assets/images/drug-development-cost-analysis/drug-development-cost-analysis-section-4-veterinary-drugs-vs-hum-bw-academic.jpg)](../../assets/images/drug-development-cost-analysis/drug-development-cost-analysis-section-4-veterinary-drugs-vs-hum-bw-academic.jpg)

Amoxicillin for your dog: 12 dollars. Amoxicillin for you: 120 dollars. Same antibiotic. You’re ten times more expensive to keep alive than your pet.

### Orphan Drugs (Full Development Cost Exposure)

The previous comparisons show 3-100× premiums, but none exceed [105x (90% CI: 72.8x-149x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-drug_cost_increase_pre1962_to_current_multiplier). **Why?** Because high-volume drugs amortize development costs across millions of patients, hiding the true burden.

**Orphan drugs reveal the full [105x (90% CI: 72.8x-149x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-drug_cost_increase_pre1962_to_current_multiplier) cost burden** because small patient populations (~200,000 or fewer in the US) mean development costs cannot be spread across many sales:

| Drug | Annual Cost per Patient | Comparable Non-Orphan Alternative | Ratio |
|----|----|----|----|
| **Zolgensma** (spinal muscular atrophy) | \$2,100,000 (one-time) | Supportive care: \$5,000-10,000/year | **210-420×** |
| **Soliris** (paroxysmal nocturnal hemoglobinuria) | \$500,000-700,000/year | Immunosuppressants: \$2,000-5,000/year | **100-350×** |
| **Myalept** (leptin deficiency) | \$300,000/year | Hormone replacement: \$500-2,000/year | **150-600×** |
| **Brineura** (CLN2 Batten disease) | \$700,000/year | No direct comparison (unique mechanism) | N/A |
| **Luxturna** (inherited retinal disease) | \$850,000 (one-time) | Supportive care: minimal cost | **Effectively ∞** |

**The math checks out:**

$$ \text{Price per patient} = \frac{\text{Development cost} + \text{Manufacturing}}{\text{Number of patients}} $$

For a rare disease with 10,000 US patients:

- Development cost: \$2.6B (amortized over 10 years, 100,000 patient-years)
- Per-patient cost: \$2.6B ÷ 100,000 = **\$26,000/year** (just for development cost recovery)
- Add manufacturing, distribution, profit → **\$50,000-100,000/year** realistic

For ultra-rare diseases (1,000 patients):

- Per-patient development cost: \$2.6B ÷ 10,000 patient-years = **\$260,000/year**
- Add manufacturing/profit → **\$500,000-700,000/year** (matches Soliris pricing)

**This is why orphan drugs cost \$300,000-\$700,000/year:** The [105x (90% CI: 72.8x-149x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-drug_cost_increase_pre1962_to_current_multiplier) development cost increase means small patient populations cannot amortize the regulatory burden.

### Historical Price Trajectory (Penicillin: 1942 vs. 2024)

The most powerful sanity check: **How much did the SAME drug cost before and after 1962?**

**Penicillin production cost:**

- 1942 (first mass production): \$20 per dose (equivalent to ~\$400 in 2024 dollars, during wartime scarcity)
- 1950s (post-scaling): \$0.05 per dose (equivalent to ~\$0.60 in 2024 dollars)
- 2024 (generic amoxicillin): \$0.50-2.00 per dose

Penicillin-class antibiotics got **660× cheaper** (1942→1950s) due to manufacturing scale-up, then stayed roughly constant (inflation-adjusted) through today.

**But if a NEW antibiotic were developed today:**

- Development cost: \$2.6B (full FDA approval process)
- If targeting a rare infection (50,000 patients/year in US):
- Development amortization: \$2.6B ÷ (50,000 × 10 years) = **\$5,200 per patient**
- Manufacturing cost: \$0.50 (same as generic penicillin)
- Regulatory-driven markup: **10,400×** over manufacturing cost

This explains why pharmaceutical companies **stopped developing new antibiotics**: The [105x (90% CI: 72.8x-149x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-drug_cost_increase_pre1962_to_current_multiplier) development cost increase makes it unprofitable to develop drugs for conditions that resolve quickly (antibiotics treat infections in days/weeks, unlike chronic disease drugs taken for decades).

### Cross-Validation: All Six Checks Confirm [105x (90% CI: 72.8x-149x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-drug_cost_increase_pre1962_to_current_multiplier) Development Cost Increase

| Comparison Type | Price Multiplier | What It Isolates |
|----|----|----|
| Generic vs. Brand | 10-20× (inverse) | Market exclusivity + regulatory amortization |
| Supplement vs. Prescription | 10-100× | Full FDA approval process |
| Compounded vs. FDA-approved | 3-16× | FDA approval overhead |
| Veterinary vs. Human | 3-20× | Human drug regulatory pathway |
| **Orphan drugs vs. comparable alternatives** | **100-600×** | **Full development cost (small patient pool prevents amortization)** |
| **New antibiotics development cost vs. manufacturing** | **10,400×** | **Complete regulatory burden for acute-use drugs** |

The first four comparisons show 3-100x premiums. That’s because popular drugs **hide** the [105x (90% CI: 72.8x-149x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-drug_cost_increase_pre1962_to_current_multiplier) cost by spreading it across millions of patients.

The last two **reveal the full burden**:

- **Orphan drugs** serve 10,000-200,000 patients. Not enough to spread the cost. Prices hit **\$300,000-\$2,100,000/year**.
  - **Zolgensma** (\$2.1M): **210-420x** vs. supportive care
  - **Myalept** (\$300K/year): **150-600x** vs. standard hormones
  - **Soliris** (\$500-700K/year): **100-350x** vs. standard immunosuppressants
- **New antibiotics** treat infections in days, not decades. Can’t recover a \$2.6B development cost on a 7-day prescription. So pharma **stopped making them**.

**Three drugs show 150-600x price premiums.** That’s the [105x (90% CI: 72.8x-149x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-drug_cost_increase_pre1962_to_current_multiplier) development cost increase, visible in plain sight wherever small patient pools can’t absorb the regulatory burden.

## Addressing Common Objections

### “That can’t be right. It’s too high!”

**Response:** Multiple independent sources confirm a 100× to 400× increase:

- This calculation: **[105x (90% CI: 72.8x-149x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-drug_cost_increase_pre1962_to_current_multiplier)**
- Baily study progression: **~116×** (based on 1980 baseline)
- Tufts CSDD: Consistent with these estimates when accounting for methodology

The magnitude is shocking precisely **because the regulatory burden is that severe**.

[![Five different studies agree: regulation made drugs 100 to 400 times more expensive. Consensus: rare in science, common in obvious disasters.](../../assets/images/drug-development-cost-analysis/drug-development-cost-analysis-section-that-can-t-be-right-it-s-too-high-bw-academic.jpg)](../../assets/images/drug-development-cost-analysis/drug-development-cost-analysis-section-that-can-t-be-right-it-s-too-high-bw-academic.jpg)

Five different studies agree: regulation made drugs 100 to 400 times more expensive. Consensus: rare in science, common in obvious disasters.

### “Doesn’t that include marketing costs?”

[![What’s in the 2.6 billion: research, trials, failures. What’s not in it: marketing, manufacturing, executive bonuses. The real number is higher. Everything is worse than you think.](../../assets/images/drug-development-cost-analysis/drug-development-cost-analysis-section-doesn-t-that-include-marketing-costs-bw-academic.jpg)](../../assets/images/drug-development-cost-analysis/drug-development-cost-analysis-section-doesn-t-that-include-marketing-costs-bw-academic.jpg)

What’s in the 2.6 billion: research, trials, failures. What’s not in it: marketing, manufacturing, executive bonuses. The real number is higher. Everything is worse than you think.

**No.** The Tufts CSDD \$2.6B figure explicitly **excludes**:

- Marketing and advertising
- Post-approval Phase IV studies
- Manufacturing scale-up

It includes **only**:

- Preclinical research
- Clinical trials (Phases I-III)
- Regulatory affairs
- Cost of capital
- Cost of failures

### “What about technological improvements reducing costs?”

**That’s the point.** Despite massive technological improvements:

- **Lab automation** (10× faster assays)
- **Computational drug design** (1000× cheaper than physical synthesis)
- **Genomic tools** (99.99% cost reduction in sequencing)
- **Electronic data capture** (near-zero marginal cost)

…costs still increased **[105x (90% CI: 72.8x-149x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-drug_cost_increase_pre1962_to_current_multiplier)** in real terms. This demonstrates the **overwhelming regulatory burden** that swamps all efficiency gains.

[![Computers got a million times cheaper. Labs got a million times faster. Drugs got a million times more expensive. You’re doing it backwards.](../../assets/images/drug-development-cost-analysis/drug-development-cost-analysis-section-what-about-technological-bw-academic.jpg)](../../assets/images/drug-development-cost-analysis/drug-development-cost-analysis-section-what-about-technological-bw-academic.jpg)

Computers got a million times cheaper. Labs got a million times faster. Drugs got a million times more expensive. You’re doing it backwards.

## What This Means

Three conclusions from a [105x (90% CI: 72.8x-149x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-drug_cost_increase_pre1962_to_current_multiplier) cost increase:

### Fixing This Has Massive ROI

Cut drug development costs just **20%** by streamlining trials:

$$ \text{Annual savings} = \$2.6B \times 0.20 \times 50 \text{ drugs/year} = \$26B/\text{year} $$

### Pre-1962 System Wasn’t Broken

Drugs developed under the pre-1962 regime (safety-only testing):

- **Antibiotics** (penicillin, streptomycin, tetracycline)
- **Vaccines** (polio, measles, rubella)
- **Insulin** (commercial production)
- **Antihistamines** (benadryl, dramamine)
- **Beta blockers** (propranolol)

These drugs saved **millions of lives** and remain in use today. The thalidomide tragedy was **a safety failure**, not an efficacy failure. The pre-1962 system already required safety testing.

[![Before 1962, you invented polio vaccines, antibiotics, and insulin. After 1962, you invented forms. The forms won.](../../assets/images/drug-development-cost-analysis/drug-development-cost-analysis-section-2-pre-1962-system-wasn-t-broken-bw-academic.jpg)](../../assets/images/drug-development-cost-analysis/drug-development-cost-analysis-section-2-pre-1962-system-wasn-t-broken-bw-academic.jpg)

Before 1962, you invented polio vaccines, antibiotics, and insulin. After 1962, you invented forms. The forms won.

### Real-World Evidence Can Reverse This

The [RECOVERY trial](../../knowledge/appendix/recovery-trial.llms.md) demonstrated that **simple randomization** can:

- Reduce cost per patient by **[82x (90% CI: 21.4x-195x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-recovery_trial_cost_reduction_factor)**
- Maintain scientific rigor
- Accelerate results (6 months vs. 5+ years)

## Conclusion

The [105x (90% CI: 72.8x-149x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-drug_cost_increase_pre1962_to_current_multiplier) real cost increase is well-documented, conservative (some estimates hit 400x), and fixable. Multiple independent sources agree on the trajectory. The math is transparent. And the [RECOVERY trial](../../knowledge/appendix/recovery-trial.llms.md) proved you can reverse it.

One law in 1962 turned a 2-3 year, \$1.2M process into a 10-15 year, \$2.6B gauntlet. That’s not the cost of science. That’s the cost of paperwork.

## References

- Congressional testimony (1977): Pre-1962 drug costs^([7](../references.llms.md#ref-pre-1962-drug-costs-congressional-testimony))
- Tufts CSDD (2014): Current drug development costs^([8](../references.llms.md#ref-tufts-drug-development-cost-2021))
- RECOVERY trial: [Low-cost trial methodology](../../knowledge/appendix/recovery-trial.llms.md)
- Regulatory Mortality: [Detailed cost analysis](https://invisible-graveyard.warondisease.org)

## Technical Parameters

| Parameter | Value | Source |
|----|----|----|
| `PRE_1962_DRUG_DEVELOPMENT_COST` | [\$24.7 million (95% CI: \$19.5 million-\$30 million)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-pre_1962_drug_development_cost_2024_usd) | Congressional testimony (1962 dollars) |
| `PHARMA_DRUG_DEVELOPMENT_COST_CURRENT` | [\$2.6 billion (95% CI: \$1.5 billion-\$4 billion)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-pharma_drug_development_cost_current) | Tufts CSDD (2013 dollars) |
| `DRUG_COST_INCREASE_PRE1962_TO_CURRENT_MULTIPLIER` | [105x (90% CI: 72.8x-149x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-drug_cost_increase_pre1962_to_current_multiplier) | Calculated with inflation adjustment |
| `TRIAL_COST_REDUCTION_FACTOR` | [82x (90% CI: 21.4x-195x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-recovery_trial_cost_reduction_factor) | Per-patient cost increase |

1\.

Baily, M. N. Pre-1962 drug development costs (baily 1972). *Baily (1972)* <https://samizdathealth.org/wp-content/uploads/2020/12/hlthaff.1.2.6.pdf> (1972)

*Pre-1962: Average cost per new chemical entity (NCE) was \$6.5 million (1980 dollars) Inflation-adjusted to 2024 dollars: \$6.5M (1980) ≈ \$22.5M (2024), using CPI multiplier of 3.46× Real cost increase (inflation-adjusted): \$22.5M (pre-1962) → \$2,600M (2024) = 116× increase Note: This represents the most comprehensive academic estimate of pre-1962 drug development costs based on empirical industry data Additional sources: https://samizdathealth.org/wp-content/uploads/2020/12/hlthaff.1.2.6.pdf*

.

2\.

U.S. Bureau of Labor Statistics. [CPI inflation calculator](https://www.bls.gov/data/inflation_calculator.htm). (2024)

*CPI-U (1980): 82.4 CPI-U (2024): 313.5 Inflation multiplier (1980-2024): 3.80× Cumulative inflation: 280.48% Average annual inflation rate: 3.08% Note: Official U.S. government inflation data using Consumer Price Index for All Urban Consumers (CPI-U). Additional sources: https://www.bls.gov/data/inflation_calculator.htm*

.

3\.

Ramsberg, J. & Platt, R. Pragmatic trial cost per patient (median \$97). *Learning Health Systems* <https://pmc.ncbi.nlm.nih.gov/articles/PMC6508852/> (2018)

*Meta-analysis of 108 embedded pragmatic clinical trials (2006-2016). The median cost per patient was \$97 (IQR \$19–\$478), based on 2015 dollars. 25% of trials cost \<\$19/patient; 10 trials exceeded \$1,000/patient. U.S. studies median \$187 vs non-U.S. median \$27. Additional sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC6508852/*

.

4\.

DiMasi, J. A., Grabowski, H. G. & Hansen, R. W. Innovation in the pharmaceutical industry: New estimates of r&d costs. *Journal of Health Economics* <https://doi.org/10.1016/j.jhealeco.2016.01.012> (2016) doi:[10.1016/j.jhealeco.2016.01.012](https://doi.org/10.1016/j.jhealeco.2016.01.012).

5\.

Tufts Center for the Study of Drug Development. [Cost to develop and win marketing approval for a new drug is \$2.6 billion](https://www.globenewswire.com/news-release/2014/11/18/1187467/0/en/Cost-to-Develop-and-Win-Marketing-Approval-for-a-New-Drug-Is-2-6-Billion-According-to-the-Tufts-Center-for-the-Study-of-Drug-Development.html). (2014).

6\.

FDA. Generic drug substitution savings. *FDA* <https://www.fda.gov/drugs/generic-drugs/generic-drug-facts>.

7\.

*Pre-1962 Drug Development Costs (Congressional Testimony, Alternative Estimate)*. <https://www.congress.gov/95/crecb/1977/04/21/GPO-CRECB-1977-pt10-2-3.pdf> (1977)

*1962: Average cost \$1.2 million (in 1962 dollars) 1972: \$11.5 million 1977: Projected \$40 million Inflation-adjusted to 2024 dollars: \$1.2M (1962) ≈ \$12M (2024), using CPI multiplier of  10× Real cost increase (inflation-adjusted): \$12M (1962) → \$2,600M (2024) = 217× increase Note: Lower estimate than Baily (1972); may reflect incomplete cost accounting or different drug types. Baily’s \$6.5M (1980 dollars) = \$22.5M (2024 dollars) is the more rigorous academic estimate Additional sources: https://www.congress.gov/95/crecb/1977/04/21/GPO-CRECB-1977-pt10-2-3.pdf*

.

8\.

Tufts Center for the Study of Drug Development. Tufts center drug development cost estimate 2021. (2021)

*Total cost to develop a new drug estimated at \$2.6 billion as of 2021, nearly a 3-fold increase from \$802 million in 2003 (inflation-adjusted).*

9\.

Tufts CSDD. Cost of drug development.

*Various estimates suggest \$1.0 - \$2.5 billion to bring a new drug from discovery through FDA approval, spread across  10 years. Tufts Center for the Study of Drug Development often cited for \$1.0 - \$2.6 billion/drug. Industry reports (IQVIA, Deloitte) also highlight \$2+ billion figures.*

10\.

C&EN. Annual number of new drugs approved globally:  50. *C&EN* <https://cen.acs.org/pharmaceuticals/50-new-drugs-received-FDA/103/i2> (2025)

*50 new drugs approved annually Additional sources: https://cen.acs.org/pharmaceuticals/50-new-drugs-received-FDA/103/i2 \| https://www.fda.gov/drugs/development-approval-process-drugs/novel-drug-approvals-fda*

.